A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Trial Profile

A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Prednisolone acetate (Primary)
  • Indications Anterior uveitis
  • Focus Registrational; Therapeutic Use
  • Sponsors EyeGate Pharma
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 1 Oct 2017 to 1 Feb 2018.
    • 25 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 23 Feb 2017 According to an EyeGate Pharmaceuticals media release, the company expects to complete enrollment in the third quarter of 2017 and to report top-line data in the fourth quarter of 2017, leading to an NDA submission by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top